Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

G-007

Supelco

Gabapentin solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C9H17NO2
Numéro CAS:
60142-96-3
Poids moléculaire :
171.24
Numéro MDL:
MFCD00865286
Code UNSPSC :
41116107
ID de substance PubChem :
329799797
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Caractéristiques

Snap-N-Spike®/Snap-N-Shoot®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

Concentration

1.0 mg/mL in methanol

Application(s)

pharmaceutical (small molecule)

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

NCC1(CCCCC1)CC(O)=O

InChI

1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)

Clé InChI

UGJMXCAKCUNAIE-UHFFFAOYSA-N

Informations sur le gène

human ... CACNA1A(773) , CACNA1B(774) , CACNA1C(775) , CACNA1D(776) , CACNA1E(777) , CACNA1F(778) , CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911) , CACNA1S(779) , CACNA2D1(781) , CACNA2D2(9254) , CACNA2D3(55799) , CACNA2D4(93589) , CACNB1(782) , CACNB2(783) , CACNB3(784) , CACNB4(785) , CACNG1(786) , CACNG2(10369) , CACNG3(10368) , CACNG4(27092) , CACNG5(27091) , CACNG6(59285) , CACNG7(59284) , CACNG8(59283)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

Sold under the trade names Neurontin®, Nupentin, or Gabarone, gabapentin is an anticonvulsant drug used primarily for treatment of seizures, fibromyalgia, and chronic neuropathic pain. This certified Snap-N-Spike® Reference Solution is suitable for use in GC/MS or LC/MS applications from forensic analysis, clinical toxicology and pain prescription monitoring to urine drug testing.

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Neurontin is a registered trademark of Warner-Lambert Co.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

G-017

Gabapentin-D10 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

G-901

Gabapentin-D10 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-066

Prégabaline solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-072

Prégabaline-D6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

V-022

Vigabatrin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

G-007S

Gabapentin solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Prégabaline solution 10.0 mg/mL in water, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

P-120

Prégabaline solution

Gabapentin European Pharmacopoeia (EP) Reference Standard

Y0001280

Gabapentin

Norbuprenorphine solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

N-059

Norbuprenorphine solution

Carbamazepine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1067

Carbamazepine

Pregabalin European Pharmacopoeia (EP) Reference Standard

Y0001805

Pregabalin

Diazepam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

D-907

Diazepam solution

Mark P Jensen et al.
The Clinical journal of pain, 29(9), 770-774 (2013-02-02)
This study evaluated the long-term safety and tolerability of a gastroretentive formulation of gabapentin (G-GR) and its effect on weight gain in postherpetic neuralgia (PHN) patients participating in a 14-week, open-label extension to a 10-week double-blind study. Patients with PHN
Jen-Kun Cheng et al.
Journal of pharmacological sciences, 100(5), 471-486 (2006-02-14)
Gabapentin, a gamma-aminobutyric acid (GABA) analogue anticonvulsant, is also an effective analgesic agent in neuropathic and inflammatory, but not acute, pain systemically and intrathecally. Other clinical indications such as anxiety, bipolar disorder, and hot flashes have also been proposed. Since
Richard Rauck et al.
Anesthesiology, 119(3), 675-686 (2013-07-10)
Oral gabapentin is approved as an anticonvulsant medication and to treat postherpetic neuralgia. Its nonopioid properties and presumed spinal site of analgesic action made the study on intrathecal gabapentin attractive to establish the minimum effective dose for a later, pivotal
Adam Bisaga et al.
Drug and alcohol dependence, 81(3), 267-274 (2005-09-20)
In laboratory animals, augmentation of GABA neurotransmission results in inhibition of cocaine self-administration and inhibition of reinstatement to cocaine-seeking behaviors. If parallel effects were observed in humans, GABA-ergic medication should be effective both in the abstinence-induction as well as in
Érica C Marchiori et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 71(12), 2115-2122 (2013-09-03)
To estimate the prevalence of, risk factors for, and clinical course of neuropathic pain (NPP) after sagittal split ramus osteotomy (SSRO) of the mandible in a large cohort of patients. A retrospective cohort of all patients who underwent SSRO at
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique